MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Search

10X Genomics Inc (Class A)

Open

SectorGezondheidszorg

12.74 2.99

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.3

Max

12.95

Belangrijke statistieken

By Trading Economics

Inkomsten

69M

35M

Verkoop

18M

173M

EPS

0.28

Winstmarge

19.975

Werknemers

1,306

EBITDA

86M

47M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+20.42% upside

Dividenden

By Dow Jones

Volgende Winsten

28 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-225M

1.5B

Vorige openingsprijs

9.75

Vorige sluitingsprijs

12.74

Nieuwssentiment

By Acuity

17%

83%

27 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

10X Genomics Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 okt 2025, 23:30 UTC

Populaire aandelen

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 okt 2025, 21:21 UTC

Winsten

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 okt 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 okt 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 okt 2025, 23:39 UTC

Marktinformatie

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 okt 2025, 23:00 UTC

Marktinformatie

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 okt 2025, 22:54 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Scales's JV Buyout Lauded by Bull -- Market Talk

2 okt 2025, 22:54 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Forex and Fixed Income Roundup: Market Talk

2 okt 2025, 22:46 UTC

Marktinformatie

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 okt 2025, 22:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 okt 2025, 21:17 UTC

Acquisities, Fusies, Overnames

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 okt 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

2 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 okt 2025, 20:49 UTC

Acquisities, Fusies, Overnames

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 okt 2025, 20:00 UTC

Acquisities, Fusies, Overnames

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 okt 2025, 19:20 UTC

Marktinformatie

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 okt 2025, 19:10 UTC

Marktinformatie

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 okt 2025, 19:04 UTC

Marktinformatie

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 okt 2025, 18:43 UTC

Acquisities, Fusies, Overnames

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer Vergelijking

Prijswijziging

10X Genomics Inc (Class A) Prognose

Koersdoel

By TipRanks

20.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14.92 USD  20.42%

Hoogste 17 USD

Laagste 13 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor 10X Genomics Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

5

Buy

8

Hold

0

Sell

Technische score

By Trading Central

8.32 / 8.63Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

27 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat